Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…Abstract Number: 2487 • 2019 ACR/ARP Annual Meeting
Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs which are regulating physiologic and pathological processes. In numerous diseases specific miRNA signatures have been identified and can…Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…Abstract Number: 1648 • 2018 ACR/ARHP Annual Meeting
Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
Background/Purpose: The BIOmarkers of COMorbidities (BIOCOM) in psoriasis study is a longitudinal study which aims to identify clinical, genetic or protein biomarker features associated with…Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…Abstract Number: 2058 • 2018 ACR/ARHP Annual Meeting
Effects of Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and Psoriatic Disease
Background/Purpose: Psoriatic Arthritis (PsA) affects up to 30% patients with psoriasis and is characterized by widespread synovio-entheseal inflammation. Physiologically, the human gut microbiota metabolizes dietary…Abstract Number: 2071 • 2018 ACR/ARHP Annual Meeting
Inflammation at Distant Immunocompetent Sites Combined with a Protocol of Forced Exercise Induces Mild Joint Inflammation
Background/Purpose: Psoriatic arthritis is a chronic joint disease clinically associated with psoriasis. Some patients also have signs of inflammatory bowel disease. Enthesitis, inflammation at the…Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting
Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…Abstract Number: 2134 • 2018 ACR/ARHP Annual Meeting
Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired…Abstract Number: 2560 • 2018 ACR/ARHP Annual Meeting
Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies
Background/Purpose: VOYAGE 1 & 2 were the pivotal Ph3 GUS trials for plaque PsO.1,2 Here we compare efficacy of GUS vs PBO & adalimumab (ADA)…Abstract Number: 663 • 2018 ACR/ARHP Annual Meeting
Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory condition characterized by the clinical domains of arthritis, enthesitis, dactylitis, spondylitis, and psoriasis. While it is known…Abstract Number: 683 • 2018 ACR/ARHP Annual Meeting
Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis
Background/Purpose: Psoriatic Arthritis (PSA) is preceded by the presence of cutaneous psoriasis (PS) in approximately 80% of the cases. We consider relevant to have tools…Abstract Number: 993 • 2018 ACR/ARHP Annual Meeting
Elucidating the Role of the Lymphatic System in the Pathogenesis of Psoriasis and Psoriatic Arthritis
Background/Purpose: Psoriasis is a common T-cell driven inflammatory skin disorder that is featured by immune cell infiltration, and vasculopathy of both blood and lymphatic vasculature.…Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…
- 1
- 2
- 3
- …
- 6
- Next Page »